Testosterone After Ovary Removal: Surgical Menopause, Androgen Loss, and the Case for Ovarian Preservation

If both of your ovaries were removed during a hysterectomy or another pelvic surgery, you went through surgical menopause overnight. Most of the conversation afterward is about estrogen, but testosterone after ovary removal drops just as suddenly, and that androgen loss affects your heart, brain, bones, muscles, bladder and sexual health. Below: why ovaries were once treated as “spare parts,” what the research shows about oophorectomy side effects, why ovarian preservation is now the standard, and how we restore hormones for women in Sandy, UT and across the Salt Lake Valley, including compounded and bioidentical options.

Ovaries Are Lifelong Endocrine Organs, Not “Spare Parts”

For decades, surgeons performed elective bilateral oophorectomies (removal of both ovaries) during routine or indicated hysterectomies, on the belief that once a woman finished having children her ovaries were functionally obsolete. Treating ovaries as reproductive vessels rather than lifelong, dynamic endocrine organs was a catastrophic failure of medical messaging, and millions of women underwent abrupt, iatrogenic castration in the name of prevention.

Why Ovaries Were Removed, and What Changed

The driver was fear of ovarian cancer, which is notoriously hard to detect early and has a high mortality rate. As long-term data accumulated, the American College of Obstetricians and Gynecologists (ACOG) scaled back its recommendations: the age cutoff for routine ovary removal moved from 45, to 50, to 60. Current guidelines favor lifetime ovarian preservation whenever benign disease permits [1, 2].

The shift came from gynecologic oncology: most high-grade serous ovarian carcinomas arise not in the ovary but in the lining of the fimbriated ends of the fallopian tubes. A bilateral salpingectomy (removing the tubes while keeping healthy ovaries) reduces ovarian cancer risk by approximately 80% [1, 2], without surgical castration or the loss of continuous steroidogenesis. Intact ovaries keep making steroid hormones for life; removing them collapses the female androgen pool, with effects on every major organ system [3].

The Castration Paradox: What Oophorectomy Does to Your Hormones

• Natural menopause unfolds gradually over several years.
• Surgical menopause is an abrupt castration event. Ovarian hormone production stops overnight.

Public messaging focuses on estrogen, but the androgen collapse is just as devastating. Approximately 80% of the total steroid output of ovarian tissue is testosterone. Circulating testosterone in women comes from ovarian secretion, adrenal production and conversion of precursors in other tissues; bilateral oophorectomy removes the main direct contributor.

This exposes a double standard. Prophylactic orchiectomy is never offered to men having lower abdominal surgery such as inguinal hernia repair, because testes are recognized as vital to health. Women have historically undergone the equivalent endocrine castration without informed consent about losing their primary androgen-producing organs.

Female Androgen Deficiency Is Diagnostically Erased

ICD-10 has billing codes for events as rare as W61.12XA, “struck by a macaw,” yet there is zero ICD-10 diagnostic code for female androgen insufficiency.

Male Hypogonadism / Erectile Dysfunction	Female Androgen Deficiency
ICD-10 coding: Specific, billable codes (e.g., E29.1 for male hypogonadism; F52.21 for erectile dysfunction).	ICD-10 coding: Zero diagnostic billing codes for female androgen deficiency or insufficiency.
Diagnostic thresholds: Clear, standardized lab cutoffs (e.g., total testosterone < 300 ng/dL) recognized by guidelines.	Diagnostic thresholds: Variable, arbitrary reference ranges where serum levels near zero are wrongly flagged as “normal.”
Clinical standard: Immediate treatment when a man presents with symptoms or reports loss of performance.	Clinical standard: Guidelines require proof of subjective “distress” about low libido before treatment is considered.
Regulatory approval: Dozens of FDA-approved oral, transdermal, injectable and pellet formulations.	Regulatory approval: Zero FDA-approved female testosterone preparations in the United States.

Surgically menopausal women are left with no formal diagnosis and no approved treatment pathway.

Heart and Metabolic Health After Ovary Removal

In women, testosterone is a global metabolic steroid, not just a “male” hormone (see The Missing Hormone: Why Women Need Testosterone Too). Sex steroids are lipid-soluble: they diffuse into cells and bind nuclear receptors, changing mRNA expression and protein synthesis. Virtually every nucleated cell is a target, including endothelial cells lining blood vessels, vascular smooth muscle cells and cardiomyocytes (heart muscle cells).

• The ASPREE trial: In more than 5,000 postmenopausal women (average age 75) followed for about 4.5 years, those in the highest quartile of natural testosterone had a 43% reduction in major adverse cardiovascular events (MACE) compared with the lowest quartile [4].
• Nitric oxide and blood vessels: Testosterone up-regulates endothelial nitric oxide synthase (eNOS) via androgen receptors in the vessel lining, producing acute arterial vasodilation, lower peripheral vascular resistance and preserved vascular reactivity. A 2001 Journal of Clinical Endocrinology & Metabolism study found testosterone quickly and measurably improved brachial artery flow-mediated dilation in postmenopausal women through this pathway [5].
• Heart muscle: The myocardium has the highest density of androgen receptors of any tissue. Testosterone supports contractility, cellular energy production and cardiac output. Double-blind randomized controlled trials in congestive heart failure show significant improvements in exercise capacity, peak oxygen consumption (VO2 max) and cardiac performance [6]. Dr. Franck Mauvais-Jarvis has emphasized that sex steroids are vital regulators of vascular smooth muscle tone and heart health in both sexes [7].

When oophorectomy eliminates ovarian androgen production, cardiovascular risk rises [3] and neurocognitive decline accelerates [8].

Brain Health, Mood, and Cognition After Surgical Menopause

In the brain, sex steroids act as neurosteroids governing synaptic plasticity, neuroinflammation, neurotransmitter synthesis and cerebral glucose metabolism.

Dementia Risk vs. Breast Cancer Fear

Hormone conversations are dominated by breast cancer fear, yet dementia is a far greater statistical threat to aging women [9]:

• Risk at age 60: For every one woman diagnosed with breast cancer (a condition with a 90% long-term survival rate), two women are diagnosed with dementia.
• Disproportionate burden: Women account for nearly two-thirds of all Alzheimer’s and dementia cases worldwide.

Women who have their ovaries removed before natural menopause have a higher long-term risk of cognitive impairment or dementia [8]. Estrogen deficiency mainly shows up as verbal retrieval and short-term memory lapses (trouble recalling nouns and names); testosterone is essential for processing speed, executive function, spatial orientation and mood stability.

Testosterone and Breast Cancer: Dr. Rebecca Glaser’s Research

From the 1940s through the 1990s, high-dose testosterone was a standard treatment for metastatic breast cancer [10]. Dr. Rebecca Glaser, a breast cancer surgeon and researcher, published 15-year prospective data on breast cancer survivors treated with subcutaneous bioidentical testosterone pellets combined with an aromatase inhibitor, showing significantly lower recurrence rates and better long-term survival than standard tamoxifen or oral aromatase inhibitor monotherapy [11, 12]. Observational studies of transgender men on long-term, high-dose testosterone also show lower breast cancer incidence than in cisgender women [13], supporting a protective, anti-proliferative effect. More: Hormone Therapy and Breast Cancer: Separating Myth from Evidence.

Depression, Fatigue, and SSRIs After Oophorectomy

The sudden loss of neurosteroids often shows up as brain fog, deep fatigue, executive dysfunction and clinical depression, which are commonly treated with SSRIs. That can add harm:

1. Direct androgen suppression: SSRIs reduce bioavailable testosterone.
2. Sexual dysfunction: Up to 70% of women on SSRIs have low libido, and roughly 15% have complete anorgasmia.
3. Worse fatigue: Further blunting androgens worsens fatigue and executive dysfunction without addressing the hormone deficiency.

A 2009 trial in women with treatment-resistant depression who had failed SSRI therapy found that adding a low-dose transdermal testosterone patch achieved a 67% response rate within 8 weeks, nearly double standard antidepressant monotherapy [14]. A UK menopause clinic study reported that 47% of 510 women already on hormone therapy had better mood after four months of added transdermal testosterone [15].

Bones, Muscle, “Sarporosis,” and Urogenital Health

Bone Collagen and “Sarporosis”

Standard bone care focuses on bone mineral density (BMD). Mineral gives hardness, but structural collagen makes up one-third of bone mass and provides the shock-absorbing resilience that prevents fractures. Testosterone and estradiol both drive collagen production by osteoblasts. In a two-year randomized trial, postmenopausal women given estradiol plus testosterone implants gained more spine and hip bone density than women given estradiol alone [16] (see Hormones, Menopause, and Bone Health).

“Sarporosis” is the combined loss of muscle (sarcopenia) and bone matrix (osteoporosis). Testosterone helps preserve type II muscle fiber density, motor balance and fall prevention. In a randomized trial of women after hysterectomy (with or without oophorectomy), testosterone improved lean body mass and muscle power at the highest dose studied [17]. Clinically, bioidentical testosterone pellets given to women with non-healing fractures and unmeasurable baseline testosterone led to rapid, X-ray-confirmed fracture healing within two months.

Testosterone and Endometrial Safety

A 2007 study on endometrial proliferation found [18]:

• Testosterone alone caused zero endometrial proliferation.
• Testosterone added to estrogen down-regulated estrogen receptors in uterine and breast tissue, reducing estrogen-driven endometrial proliferation from 50% to 28%.

This makes testosterone a valuable tool for balancing unopposed estrogen, including in endometriosis, uterine fibroids and heavy uterine bleeding. (Progesterone also protects the uterine lining; see Progesterone 101.)

Genitourinary Syndrome of Menopause (GSM)

The bladder, urethra, outer third of the vagina and labia develop from the urogenital sinus, which is dense with androgen receptors. Local vaginal estrogen alone fails to resolve GSM in roughly 50% of surgically menopausal women. Based on Sexual Medicine Reviews (2020) [19], adding intravaginal or systemic testosterone:

• restores tissue volume, muscle tone and microvascular blood flow to the vulva and vagina
• re-establishes natural lubrication
• reverses clitoral regression and atrophy, restoring normal nerve density and erectile structure
• eliminates deep and superficial dyspareunia (painful intercourse)

A personalized compounded option: Instead of single-agent commercial products like IntraRosa (prasterone/DHEA suppositories, upwards of $300 per month), clinicians can work with compounding pharmacies on an affordable, customized vaginal cream combining DHEA, testosterone and estradiol that directly targets urogenital androgen receptors. Learn more in Vaginal Dryness, Painful Intimacy, or Frequent UTIs After Menopause?

Sleep and nocturia: Testosterone is needed for deep, slow-wave sleep. Clinical literature from the 1940s described nocturia (waking at night to urinate) as an endocrine indication for testosterone replacement, reflecting its effect on bladder (detrusor) tone and sleep architecture.

Regulatory Double Standards and Clinical Realities

The FDA Gap for Women’s Testosterone

Sildenafil (Viagra) went from clinical trials to FDA approval in just two years. In 2004, data for a female testosterone patch (Intrinsa) for women who had a hysterectomy and oophorectomy were submitted to the FDA; randomized, placebo-controlled trials showed it improved sexual desire and satisfying sexual activity [20, 21]. The advisory panel still rejected it, describing female androgen deficiency as of “unclear clinical significance.” Intrinsa was later approved in Europe and used safely for 5 to 6 years with zero reported adverse safety events, then discontinued only because the manufacturer found it commercially unprofitable [22].

Why “Normal” Testosterone Labs Can Mislead

Commercial direct immunoassays are notoriously inaccurate at low female levels and often report near-zero testosterone as “normal” (see Low Testosterone Labs in Sandy, UT: Why “Normal” Doesn’t Mean Optimal). Key principles for reading hormone lab panels:

1. FSH monitoring: After menopause or surgical castration, FSH rises above 40 mIU/mL. Effective systemic restoration should bring it down to about the 20 mIU/mL range.
2. Re-testing pitfalls: Sublingual troches or transmucosal tabs produce sharp, short-lived spikes (often above 1,300 ng/dL an hour after a dose), so serum levels poorly reflect tissue saturation and routine re-testing often causes needless alarm.
3. Pro-hormone pool replacement: In a young woman with intact ovaries, direct testosterone secretion is roughly 20% of the active androgen pool; the rest comes from DHEA, DHEAS and androstenedione [23]. After oophorectomy, testosterone must act as a pro-hormone source to refill that broader pool.
4. Iron balance: Ferritin below 30 ng/mL is clinical anemia even with normal hemoglobin and hematocrit (H&H); ferritin below 80 ng/mL is linked to telogen effluvium (hair loss). For hair loss, take oral iron on alternate days (Monday, Wednesday and Friday) with no calcium or dairy within 6 hours, to avoid down-regulating intestinal iron receptors (the hepcidin pathway). (Related: The Paradox of Polycythemia and Iron Deficiency in Testosterone Therapy.)*I really should have called this erythrocytosis rather than polycythemia….
5. Hair and acne: Optimize thyroid, consider low-dose oral minoxidil, and stop biotin 72 hours before labs to avoid assay interference. For PCOS or high 5-alpha-reductase activity with acne, start spironolactone to block conversion to DHT in the skin before adding testosterone, with documented counseling on teratogenic (birth defect) risk.

How Testosterone Is Prescribed for Women After Ovary Removal

With no FDA-approved testosterone product for women in the U.S., compounded and bioidentical preparations are a legitimate, personalized way to restore what surgery removed, tailored to body size, symptoms and medications. Your plan is always set with your clinician.

1. Compounded transdermal testosterone cream: A small, individualized daily amount applied to thin, vascular skin such as the external labia (giving both local urogenital and systemic effects), inner arms or backs of the knees. Frail, low-body-weight or elderly patients (e.g., a 90-pound woman decades past menopause) start lower; patients on SSRIs or with severe neurological symptoms may start higher. Counseling on transfer to family members or pets is documented.
2. Subcutaneous bioidentical testosterone pellets: Placed in the upper buttock fat pad and released steadily over 3 to 4 months. Best for severe symptoms, established “sarporosis,” treatment-resistant depression or SSRI use. Hormone-naive or elderly patients start lower since pellets can’t be removed; severe depression or SSRI use may call for a higher dose to overcome androgen receptor blunting and liver clearance changes. Read Hormone Pellet Therapy in Sandy, UT: How Pellets Work. See what to expect after a female hormone pellet.

Key Takeaways

1. Ovarian preservation is primary prevention. Removing only the fallopian tubes reduces ovarian cancer risk by about 80% while preserving lifelong hormone production.
2. Oophorectomy triggers systemic androgen collapse across the cardiovascular, nervous, musculoskeletal and urogenital systems.
3. Testosterone protects the heart and brain: a 43% MACE reduction with higher natural levels, a 67% response rate in treatment-resistant depression, and research supporting safety in breast oncology.
4. Testosterone helps reverse “sarporosis” and urogenital atrophy, lowers endometrial proliferation from 50% to 28% when added to estrogen, and resolves GSM when local estrogen fails.
5. Treat the patient, not just the lab, with tailored compounded creams or pellets stratified by body size, frailty and psychiatric medications.

Frequently Asked Questions

Does removing your ovaries lower your testosterone?

Yes. The ovaries are the main direct source of testosterone in women, and approximately 80% of ovarian steroid output is testosterone. Bilateral oophorectomy removes that source overnight, causing an abrupt androgen collapse rather than the gradual change of natural menopause.

Can I lower my ovarian cancer risk without having my ovaries removed?

For many women, yes. Most high-grade serous ovarian cancers start in the fallopian tubes, so bilateral salpingectomy while keeping the ovaries reduces risk by approximately 80%. Current guidelines favor lifetime ovarian preservation whenever benign disease permits.

Is testosterone therapy safe for women with a history of breast cancer concerns?

High-dose testosterone was a standard metastatic breast cancer treatment from the 1940s through the 1990s. Dr. Rebecca Glaser’s research on pellets with an aromatase inhibitor, and data in transgender men, point to a protective effect on breast tissue. Your history should be reviewed individually.

Why does my testosterone lab say “normal” when I feel terrible?

Standard direct immunoassays are inaccurate at women’s low levels and often flag near-zero results as “normal.” We treat symptoms and use markers like FSH rather than a single serum testosterone number.

Are compounded or bioidentical hormones a legitimate option?

Yes. With no FDA-approved testosterone product for women in the U.S., compounded creams, compounded vaginal DHEA/testosterone/estradiol creams and bioidentical pellets let us personalize therapy to your body, symptoms and medications.

Where can I get testosterone therapy after ovary removal in Sandy, UT?

Nervana Medical in Sandy offers hormone therapy consultations, lab testing and individualized bioidentical hormone replacement therapy for women across Salt Lake County, including Salt Lake City, Draper, Midvale and Cottonwood Heights.

Book a Hormone Consultation in Sandy, UT

Whether your oophorectomy was last month or decades ago, it is not too late to restore what surgery took away. We start with a detailed hormone therapy consultation, review your surgical history and symptoms, and build a personalized plan that may include compounded creams, bioidentical pellets or vaginal therapies. Learn more about bioidentical hormone replacement therapy in Sandy, UT and our BHRT patient education, or book your consultation today.

This article is for general education and is not a substitute for personal medical advice. Talk with your own clinician before starting, stopping or changing any treatment.

References

1. American College of Obstetricians and Gynecologists. ACOG Strengthens Recommendations Supporting Salpingectomy for Ovarian Cancer Prevention. August 2026.
2. ACOG Committee Opinion No. 774. Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention. Obstet Gynecol. 2019;133(4):e279-e284.
3. Parker WH, et al. Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses’ Health Study. Obstet Gynecol. 2009;113(5):1027-1037.
4. Islam RM, et al. Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. Lancet Healthy Longev. 2022;3(2):e109-e118.
5. Worboys S, et al. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab. 2001;86(1):158-161.
6. Iellamo F, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol. 2010;56(16):1310-1316.
7. Mauvais-Jarvis F, et al. Metabolic benefits afforded by estradiol and testosterone in both sexes: clinical considerations. J Clin Invest. 2024;134(17):e180073.
8. Rocca WA, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074-1083.
9. Alzheimer’s Association. Women and Alzheimer’s.
10. Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res. 2009;11(5):212.
11. Glaser RL, Dimitrakakis C. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. Maturitas. 2013;76(4):342-349.
12. Glaser RL, York AE, Dimitrakakis C. Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. BMC Cancer. 2019;19(1):1271.
13. de Blok CJM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. 2019;365:l1652.
14. Miller KK, et al. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr. 2009;14(12):688-694.
15. Glynne S, et al. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study. Arch Womens Ment Health. 2025;28(3):541-550. Published online 2024.
16. Davis SR, et al. Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas. 1995;21(3):227-236.
17. Huang G, et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause. 2014;21(6):612-623.
18. Zang H, et al. Effects of testosterone treatment on endometrial proliferation in postmenopausal women. J Clin Endocrinol Metab. 2007;92(6):2169-2175.
19. Maseroli E, et al. Testosterone and vaginal function. Sex Med Rev. 2020;8(3):379-392.
20. Shifren JL, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343(10):682-688.
21. Braunstein GD, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med. 2005;165(14):1582-1589.
22. European Medicines Agency. Intrinsa: withdrawal of marketing authorisation.
23. Davis SR. Androgens in premenopausal women and women with premature ovarian insufficiency. Climacteric. 2021;24(5):459-465.